Guardant Health legal chief sells 10K shares

Guardant Health, Inc. Chief Legal Officer John G. Saia reported selling 10,000 shares of common stock in open-market transactions on May 27, 2026.

Rhea-AI Filing Summary

Guardant Health, Inc. Chief Legal Officer John G. Saia reported selling 10,000 shares of common stock in open-market transactions on May 27, 2026. The filing shows two sales: 6 shares at $126.08 per share and 9,994 shares at $125.083 per share.

A footnote explains that the reported price reflects a weighted average, with individual trades executed between $125.00 and $125.44 per share. The insider remains a shareholder after these sales, but the exact remaining position is not detailed in the provided data.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 2 txns

Insider Saia John G.

Role Chief Legal Officer

Sold 10,000 shs ($1.25M)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,994	$125.083	$1.25M
Sale	Common Stock	6	$126.08	$756.48

Holdings After Transaction: Common Stock — 35,950 shares (Direct)

Footnotes (1)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.44. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Total shares sold: 10,000 shares Price for 6-share sale: $126.08/share Price for 9,994-share sale: $125.083/share +1 more

4 metrics

Total shares sold 10,000 shares Open-market sales reported on May 27, 2026

Price for 6-share sale $126.08/share Single transaction in common stock

Price for 9,994-share sale $125.083/share Larger open-market sale of common stock

Trade price range $125.00–$125.44/share Weighted average price range across multiple executions

Key Terms

open-market sale, Common Stock, weighted average sales price, non-derivative

4 terms

open-market sale financial

"transaction_action: "open-market sale" for both common stock transactions"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" for each non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

weighted average sales price financial

"Represents the weighted average sales price per share."

non-derivative financial

"transaction_type: "non-derivative" for each reported transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardant Health (GH) report for John G. Saia?

Guardant Health reported that Chief Legal Officer John G. Saia sold 10,000 shares of common stock. The Form 4 shows two open-market sales on May 27, 2026, totaling 10,000 shares, reflecting a net sale position for this filing.

At what prices did John G. Saia sell Guardant Health (GH) shares?

The reported sales occurred around $125 per share. One transaction involved 6 shares at $126.08, and another involved 9,994 shares at $125.083, with a weighted average price across trades ranging from $125.00 to $125.44 per share.

What type of transaction did the Guardant Health (GH) Form 4 disclose?

The Form 4 disclosed open-market sales of Guardant Health common stock. Both transactions are coded "S," described as sales in open-market or private transactions, and are classified as non-derivative transactions involving common stock directly held by the reporting person.

How many Guardant Health (GH) shares did John G. Saia sell in total?

John G. Saia sold a total of 10,000 Guardant Health shares. The transaction summary aggregates 6 shares from one sale and 9,994 shares from another, resulting in 10,000 shares sold and a net-sell direction for this reporting period.

Does the Guardant Health (GH) Form 4 show any option exercises or derivative transactions?

No derivative transactions are shown in this Form 4 excerpt. The derivative summary is empty, and the transaction summary indicates zero exercises or derivative transaction counts, focusing solely on sales of non-derivative common stock.

What does the weighted average price disclosure mean in the Guardant Health (GH) Form 4?

The weighted average price reflects multiple trade executions within a price range. The footnote notes sales at prices from $125.00 to $125.44. The insider offers to provide detailed share counts at each specific price upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 06:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saia John G.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		S		9,994	D	$125.083(1)	35,956	D
Common Stock	05/27/2026		S		6	D	$126.08	35,950	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.44. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)